Diagnostic and Therapeutic Management of Episcleritis and Scleritis

• Published in: Klinische Monatsblatter fur Augenheilkunde Vol. 240; no. 5; p. 725
• Main Authors: Turgut, Ferhat, Dingerkus, Vita, Tappeiner, Christoph, Becker, Matthias
• Format: Journal Article
• Language: German
• Published: Germany 01.05.2023
• Subjects: Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Antirheumatic Agents - therapeutic use; Humans; Inflammation; Sclera; Scleritis - diagnosis; Scleritis - drug therapy; Vision Disorders - drug therapy
• ISSN: 1439-3999
• DOI: 10.1055/a-2022-0689

While episcleritis is a benign disease only affecting the episclera, scleritis is an ocular inflammation with typically severe pain and not rarely affecting adjacent tissue.Scleritis is classified into anterior and posterior forms. Anterior scleritis is further subdivided into diffuse, nodular, necrotizing with inflammation, and necrotizing scleritis without inflammation (scleromalacia perforans). A systemic disease such as rheumatoid arthritis or granulomatosis with polyangiitis is associated with up to 50% of all patients with scleritis or episcleritis, consequently a systemic work-up with blood sampling and imaging as well as collaboration with internists are necessary.Differentiating these two entities is of high importance for planning the treatment: episcleritis has a self-limited course, whereas treatment of scleritis is obligatory to protect patients from irreversible visual loss, organ damage, and furthermore reduce the risk of mortality.Treatment depending of subtype and associated systemic disease may involve non-steroidal anti-inflammatory drugs, corticosteroids, and disease-modifying anti-rheumatic drugs.